Comparison of the methods of fibrinolysis by tube thoracostomy and thoracoscopic decortication in children with stage II and III empyema: a prospective randomized study by Cobanoglu, Ufuk et al.
[page 114] [Pediatric Reports 2011; 3:e29]
Comparison of the methods 
of fibrinolysis by tube 
thoracostomy and thoracoscopic
decortication in children with
stage II and III empyema: 
a prospective randomized
study
Ufuk Cobanoglu, Fuat Sayır, Salim Bilici, 
Mehmet Melek, 
Abidin Şehitoğlu, Van State Hospital
Department of Thoracic Surgery, Van,
Turkey
Abstract 
Today, in spite of the developments in imag-
ing  methods  and  antibiotherapy,  childhood
pleural empyema is a prominent cause of mor-
bidity  and  mortality.  In  recent  years,  it  has
been shown that there has been an increase in
the frequency of pleural empyema in children,
and  antibiotic  resistance  in  microorganisms
causing pleural empyema has made treatment
difficult. Despite the many studies investigat-
ing thoracoscopic debridement and fibrinolytic
treatment  separately  in  the  management  of
this disease, there is are not enough studies
comparing these two treatments. The aim of
this  study  was  to  prospectively  compare  the
efficacy of two different treatment methods in
stage II and III empyema cases and to present
a perspective for treatment options.
We excluded from the study cases with: i)
thoracoscopic  intervention  and  fibrinolytic
agent  were  contraindicated;  ii)  immunosup-
pression or additional infection focus; iii) con-
comitant diseases, those with bronchopleural
fistula  diagnosed  radiologically,  and  Stage  I
cases. This gave a total of 54 cases: 23 (42.6%)
in stage II, and 31 (57.4%) cases in stage III.
These  patients  were  randomized  into  two
groups of 27 cases each for debridement or fib-
rinolytic  agent  application  by  video-assisted
thoracoscopic decortication (VATS). The conti-
nuity of symptoms after the operation, dura-
tion of thoracic tube in situ, and the length of
hospital stay in the VATS group were of signif-
icantly shorter duration than in the streptoki-
nase applications (P=0.0001). In 19 of 27 cases
(70.37%) in which fibrinolytic treatment was
applied  and  in  21  cases  of  27  (77.77%)  in
which  VATS  was  applied,  the  lung  was  fully
expanded and the procedure was considered
successful.  There  was  no  significant  differ-
ence with respect to success rates between the
two groups (P=0.533). The complication rate
in our cases was 12.96% and no mortality was
observed.  Similar  success  rates  in  thoraco-
scopic drainage and enzymatic debridement,
and the low cost of enzymatic drainage both
served to highlight intrapleural streptokinase
treatment as a reliable method in reducing the
need for surgery in complicated empyema.
Introduction
Bacterial  pneumonia  in  children  is  fre-
quently complicated by pleural effusion and its
incidence varies between 20 and 91%.1-3 When
pleural  effusion  is  treated  with  appropriate
antibiotics, it generally recovers spontaneous-
ly. When treated inappropriately, as a result of
fibrin deposition, the accumulation of bacteri-
al products and leukocytes in the pleural cavity
and  complicated  parapneumonic  effusion
develop.1
Causes such as socioeconomic insufficien-
cy, insensible antibiotic use, pneumonia find-
ings which mask the symptoms of empyema
resulting in delayed diagnosis, use of antibi-
otics only in the acute stages, and consequent
delays in referral to a thoracic surgery unit, all
play a role in the conversion of parapneumon-
ic effusion to empyema.
According  to  the  classification  of  the
American Thorax Association, empyema devel-
ops in three different stages:4 stage I (exuda-
tive), fluid accumulation, pH over 7.2, lactate
dehydrogenase below 1000 IU/L, glucose over
60 mg/dL, negative culture and no loculations;
stage II (fibrinopurulent), pH below 7.2, lactate
dehydrogenase over 1000 IU/I, glucose below
60 mg/dL, increased loculation or positive cul-
ture or presence of suppuration in the pleural
cavity by fibrin deposition (empyema); stage
III (organized), in addition to stage II, organ-
ized  multiloculated  parapneumonic  effusion,
trapped lung and pleural cortex formation.
Treatment  options  for  this  disease  are
observation,  therapeutic  thoracentesis,  tube
thoracostomy, intrapleural fibrinolytics, decor-
tication  with  thoracoscopy  and  thoracotomy,
and open drainage procedures.5,6
In the progress of a thoracic empyema or
complicated  (persistent  or  loculated)  parap-
neumonic  effusion,  viscous  fluid  with
obstructing fibrinous debris and non-commu-
nicating  fluid  locules  may  develop;  a  single
thoracic  tube  for  drainage  remains  insuffi-
cient.7,8 Insufficient treatment in the fibrinop-
urulent period causes pleural fluid organiza-
tion and scar formation in the pleural cavity
and the neighboring lung tissue.7 In order to
prevent  this,  and  to  clear  out  the  fibrinous
debris, numerous studies suggest video-assist-
ed thoracoscopic decortication (VATS) or fibri-
nolytic treatment in the early stages.1,9-11
The aim of this study was to prospectively
compare thoracoscopic debridement and fibri-
nolytic treatment in cases with stage II and III
empyema  and  to  present  a  perspective  for
treatment options.
Materials and Methods
Cases with contraindication against thora-
coscopic  intervention  and  fibrinolytic  agent
treatment, those with immunosuppression or
additional  infection  foci,  those  with  other
simultaneous diseases, those with radiological
bronchopleural fistulae and atage I cases were
excluded from the study. A total of 54 cases, 23
(42.6%) in stage II and 31 (57.4%) in stage III,
were  randomized  into  two  groups  of  27
patients each for debridement by VATS or fibri-
nolytic  agent  administration  (Figure  1).
Patients with hemorrhagic diathesis, stroke or
manifest hemorrhage having occurred in the
previous six months and those who had used
fibrinolytic agents for any reason in the previ-
ous two years were excluded from the fibri-
nolytic treatment group. 
Patients’  legal  guardians  and  the  institu-
tional  ethics  committee  gave  their  consent
before beginning the study.
A detailed history of disease was obtained
from  all  cases,  physical  examinations  were
performed and the duration of symptoms for
each case was evaluated.
Eighty percent of cases lived in villages and
hamlets and were children of families of a low
socioeconomic  level.  The  duration  of  symp-
toms  was  measured  as  a  mean  of  7.9  days
(range 4-10 days); difficulties in transporta-
tion and fear of terrorist attacks played a role
in this delay. No treatment was received prior
to hospitalization in 76.3% of the cases; others
had used antibiotics irregularly.
Following chest X-ray confirmation of pleu-
ral  fluid,  ultrasonography  and  computerized
tomography,  and  diagnostic  thoracentesis
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were performed. The number of cells and the
cell  characteristics  were  determined  in  the
pleural  fluid.  Furthermore,  the  pH,  protein,
glucose,  lactate  dehydrogenase  and  density
measurements in the pleural fluid and simul-
taneous serum protein, serum glucose and lac-
tate  dehydrogenase  measurements  were
taken.  The  pleural  fluid  was  sent  for  Gram
staining and culture. The presence of the fol-
lowing  characteristics  in  the  thoracentesis
fluid  led  to  the  diagnosis  of  empyema:  pH
<below 7.2, glucose below 60 mg/dL, protein
over 3 g/dL, LDH over 1000 IU, leukocyte over
5ﾥ109/L or presence of bacteria in direct exam-
ination or culture of the pleural fluid. 
In patients who were diagnosed with empye-
ma,  as  suggested  in  the  book  of  Pediatric
Respiratory  Medicine,12 empiric  treatment
with ampicillin sulbactam plus cefotaxime was
initiated. This regime was then changed when
necessary according to culture results.
An 18-24 Fr chest tube was initially inserted
in all cases and connected to a closed drainage
system and 15-20 cmH2O negative suction was
applied.  Thoracic  tube  insertion  was  per-
formed in the operating theater under intra-
venous sedation and monitorization.
In 27 cases undergoing video-assisted tho-
racoscopic  surgery,  routine  pulse  oximetry,
ECG, non-invasive blood pressure monitoring
and  end-tidal  CO2 measurements  were  rou-
tinely  performed  during  the  anesthesia.
During the procedure, the patients were placed
in the lateral decubitis position. Video equip-
ment was placed on both sides of the head. In
all  cases,  a  5  mm  30°  scope  (Karl  Storz,
Tuttlingen, Germany) was used. The fifth or
sixth intercostal space in the mid-axillary line
was selected as the primary port (5 mm) site.
The apical port (10 mm) was inserted through
the third intercostal space in order to better
visualize  the  costophrenic  sinus,  diaphragm
and  the  inferior  region.  The  third  port  (10
mm) was inserted at the auscultation triangle
in order to explore the anterior thoracic wall
and mediastinal structures. During the thora-
coscopy,  the  mediastinum,  the  pericardium,
the  chest  wall,  the  lung  and  the  diaphragm
were carefully investigated. Large cup forceps
were used to clear the debris. Fluid and debris
particles were sent for culture. When the pro-
cedure was brought to an end, the ports were
removed under direct vision and insertion of
the 18-24 Fr thoracic tube into the intrapleural
space followed. Following this, for the other 27
cases in which a remarkable amount of fluid
persisted despite drainage of less than 50 mL
determined  by  ultrasonography  and  direct
chest X-ray, enzymatic debridement was per-
formed using streptokinase (STK) (Streptase;
Hoechst, Istanbul). Before and after the fibri-
nolytic treatment, the prothrombin time, acti-
vated partial thromboplastin time (aPTT) and
fibrinogen  were  measured  and  a  complete
blood count was performed. Following steroid
and antihistaminic treatment as pre-medica-
tion, the patients were laid on one side where
the lesion was in the upper position. Normal
saline with 250,000 U/100 mL STK was admin-
istered into the pleural cavity through the tho-
racic tube in 70-120 mL volume once a day and
the tube was held by a clamp for 4-6 h. The
period  of  fibrinolytic  treatment  was  deter-
mined  as  4.45  days  (3-5  days).  The  first
drainage fluid was sent for culture and the tho-
racic tubes were connected to a -15-20 cm H20
negative suction after the clamp was opened.
The pleural fluid drainage, after the video-
assisted thoracoscopic surgery and STK appli-
cation, were recorded for 24 h.
In the VATS cases, conversions to minitho-
racotomy, and in the fibrinolysis cases, conver-
sions to VATS were considered failures.
Radiological recovery was assessed by the
criteria of Sanchez et al.13
These were: i)  maximum (normal or near-
normal pulmonary X-ray); ii) medium (pleural
effusion  cleared  in  50-80%);  iii)  minimal
(pleural effusion cleared in less than 50%); iv)
none (no changes).
In these cases, thoracic tube drainage was
terminated when the daily amount of drainage
decreased to less than 50 cc, pleural fluid cul-
ture became negative, and radiological healing
and full expansion were detected.
All  cases  were  assessed  for  a  variety  of
parameters,  such  as  the  success  of  the  two
treatment modalities, duration of thoracic tube
drainage, length of hospital stay (LHS), mor-
bidity, mortality and cost.
Article
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Statistical analysis 
The descriptive statistics for the considered
characteristics for the groups were expressed
as  median,  mean,  standard  deviation,  mini-
mum  and  maximum  values.  The  Kruskal-
Wallis test was used to compare for these char-
acteristics. The Z test was used to compare
rates. The statistical significance level of the
calculations was accepted as 5% and these cal-
culations were performed using the SPSS (ver.
13) statistical pocket program. 
Results
Twenty-two  (40.74%)  of  the  cases  were
female and 32 (59.26%) were male. Patients’
characteristics  at  the  time  of  diagnosis  are
presented in Table 1.
Pleural effusion was observed on the right
in 31% of cases and on the left in 23% of cases.
No bilateral effusion was observed. The most
frequent symptoms were respiratory distress,
cough, tachycardia and fever (Table 2).
Pleural infections were found to be conse-
quent  to  primary  empyema  in  17%  and  to
pneumonia in 37% of cases. Pathologies fre-
quently accompanying thoracic empyema were
additional  pulmonary  diseases,  such  as
bronchiectasis,  perforated  hydatid  cyst,  and
congenital pulmonary disease (20.37%) (Table
2). The results of patients’ blood, serum and
pleural  fluid  samples,  and  microbiological
analyses are presented in Table 3. Accordingly,
bacterial  growth  in  the  blood  culture  was
observed in 20 (37.03%) cases, and in the pleu-
ral  fluid  culture  in  38  (70.37%)  cases.  The
most frequently isolated (27.77%) microorgan-
ism was the Streptococcus milleri group.
The postoperative results of the cases are
shown in Table 4. Accordingly, with respect to
the duration of symptoms following the opera-
tion, duration of thoracic tube drainage, and
the length of stay in hospital, the VATS group
demonstrated shorter times than the STK with
a  statistically  significant  difference  between
groups (P=0.0001). 
The lungs were found to be fully expanded
after the procedure in 19 (70.37%) of the 27
cases receiving fibrinolytic treatment and in
21 (77.77%) of the 27 cases undergoing the
VATS procedure, and this was considered suc-
cessful (Figure 1). The difference in success
rates between the two groups was not signifi-
cant  (P=0.533).  Following  the  fibrinolytic
treatment,  8  (29.63%)  cases  in  whom  the
lungs  had  not  fully  expanded,  underwent
debridement by VATS. In one case, since lung
expansion was not achieved, decortication was
completed by thoracotomy. Six (22.23%) cases
who had undergone debridement by VATS were
further converted to thoracotomy as full expan-
sion was not achieved (Figure 1). 
Complication rate was 12.96% of cases with
no  statistical  difference  between  the  two
groups (P=0.589). In 4 (12.81%) cases receiv-
ing fibrinolytic treatment, hypertension, hem-
orrhage, sudden chest pain and sudden apho-
nia  developed.  VATS  was  performed  in  3
(11.11%)  cases;  2  cases  had  prolonged  air
leaks, and one had a wound infection. No mor-
tality was observed.
The cases were followed-up monthly for the
first three months and then on a yearly basis.
There were no remission and all patients enjoy
good health.
Discussion
Investigators  who  recommended  VATS
reported that fibrinolytic treatment is uncom-
fortable and that its resolution takes a long
time. They also reported that it is not very suc-
cessful  in  clearing  out  the  loculation.14,15
Those who defended the fibrinolytic treatment
emphasized that this method could be easily
applied, decreases the rising cost of material
use  and  preserves  patients  from  the  risk  of
morbidity posed by thoracic operations.16,17
Coote and Kay118 in 2005 investigated the
clinical results of operative and non-operative
treatment in children and adults with empye-
ma in the Cochrane Collaboration and report-
ed that fibrinolytic treatment resulted in lower
hospital costs in the early stages. In another
study,  it  was  reported  that  VATS  required  a
shorter hospital stay and gave better results.19.
However, these studies on only a few subjects
showed that larger series are needed. While in
their  retrospective  analysis  Doski  et  al.9
showed that VATS led to a shorter hospital stay
compared  to  fibrinolytics  in  children  with
empyema, Sonnappa et al.16 found a similar
length of hospital stay (mean six days) and
treatment  success  in  their  randomized
prospective study comparing fibrinolytics and
VATS decortications in children with empye-
ma. In the present study, in 3 (13%) of 30 cases
for which VATS was applied the procedure was
converted  to  mini  thoracotomy,  and  in  one
case VATS had to be re-performed; an opera-
tion was necessary in 5 (18%) of the 28 cases
to  which  fibrinolytics  were  administered.
Sonnappa  et  al.16 reported  that  fibrinolytic
treatment should be the treatment of choice in
consideration of cost.
In  the  2008,  American  Pediatric  Surgery
Association Annual Meeting, St Peter et al.20
presented their prospective randomized stud-
ies  in  which  they  administered  fibrinolytic
agents through the thoracic tube and decorti-
cations through VATS. In this series, including
18 children in each group, the length of hospi-
tal stay was 6.89 days for VATS and 6.83 days
for fibrinolytics. The cost of fibrinolytic treat-
ment was lower than VATS ($11,660 vs $7575,
P<0.01). The failure of fibrinolytic treatment
was 16.6%. 
In another study comparing these two treat-
ment  methods,  there  was  no  difference
between the two groups with respect to the
length of hospital stay, although VATS treat-
ment was expected to be shorter.14 Except for
cost, there were no significant differences in
any  secondary  result  parameters  between
groups. In this study, failure rates were similar
Aticle
Table 1. Patients’ characteristics at diagnosis.
STK (n. 27) VATS (n. 27) P
Age (years) 7.30±2.76 8.74±2.60 0.050
Sex (M/F) 17/10 9/18 0.023
Weight (kg) 25.30±6.31 26.96±8.35 0.412
Height (cm) 121±16 122±13 0.445
Oxygen support (L/min) 0.72±0.74  0.69±0.56  0.871 
Duration of symptoms in days 8.0±1.7  9.6± 4.3  0.413 
Lateral effusion thickness (mm) 73±39 79±21 0.844
Area of shadowing (%) 51±21 54±22 0.816
Table  2.  Symptoms  of  the  cases  and
accompanying diseases in the cases.
N. cases (%)
Symptoms 
Fever (>38°C) 35 (64.81)
Cough 45 (83.33)
Respiratory distress  47 (87.03)
Pyrulent mucus 16 (26.62)
Cyanosis 5 (9.25)
Tachycardia 37 (68.51)
Pleuritic type chest pain 15 (27.77)
Abdominal pain 4 (7.40)
Severe anemia 9 (16.66)
Coexisting illness
Cardiac disease  3 (5.55)
Additional respiratory disease  11(20.37)
Diabetes mellitus  2 (3.70)
Joint disease  3 (5.55)
Gastro esophageal disease  6 (11.11)
Neurological disease  2 (3.70)
Kidney disease  2 (3.70)
Liver disease  2 (3.70)
Hematologic disease 1 (1.85)[Pediatric Reports 2011; 3:e29] [page 117]
between the two groups. 
In the present study, VATS had advantages
with respect to the duration of thoracic tube
drainage, duration of symptoms after the pro-
cedure,  and  the  length  of  hospital  stay
(P=0.0001).  Fibrinolytic  treatment  had  cost
advantages (P=0.0001) (Table 4). The success
rate in those undergoing fibrinolytic treatment
was 70.37% and the failure rate was 29.62%;
these  were  77.77%  and  22.22%  for  VATS,
respectively. There was no significant differ-
ence between the two groups in success and
failure rates (P=0.533). 
The  failure  rates  for  both  groups  in  this
study  were  higher  than  that  of  other  series
(fibrinolytics  5-16%,  VATS  0-20%).9,19,20 This
result may be due to the fact that 76.3% of
patients did not receive any treatment, and in
contrast  to  other  studies9,15,19,20 most  of  the
cases (57.4%) were in stage III.
In  conclusion,  pleural  fluid  should  be
drained early and effectively before it becomes
organized and before it changes into a hard
pleural layer that is hard to manage. Drainage
should be rendered faster by thoracoscopic or
enzymatic debridement if needed. The similar
success  rates  of  thoracoscopic  drainage  and
enzymatic debridement, and the lower cost of
enzymatic  drainage,  means  that  intrapleural
streptokinase  treatment  is  an  effective  and
safe method for reducing the need for surgery
in complicated empyema.
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